# Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT00065351** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 222 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-5013

## Key facts

- **NCT ID:** NCT00065351
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07-01
- **Primary completion:** 2006-10-01
- **Final completion:** 2007-03-01
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065351, "Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00065351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*